Neuropace, Inc. (NPCE)
NASDAQ:NPCE
Want to see NPCE full AI Analyst Report?
NPCE Stock Chart & Stats
$14.09
-$0.66(-5.31%)
At close: 4:00 PM EST
$14.09
-$0.66(-5.31%)
Day’s Range― - ―
52-Week Range$7.56 - $19.60
Previous CloseN/A
Volume21.31K
Average Volume (3M)207.31K
Market Cap
$541.41M
Enterprise Value$619.59M
Total Cash (Recent Filing)$53.98M
Total Debt (Recent Filing)$70.46M
Price to Earnings (P/E)―
Beta0.75
Next Earnings
Aug 06, 2026EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.65
Shares Outstanding34,093,746
10 Day Avg. Volume163,393
30 Day Avg. Volume207,310
Financial Highlights & Ratios
PEG Ratio0.81
Price to Book (P/B)26.55
Price to Sales (P/S)5.05
P/FCF Ratio-44.56
Enterprise Value/Market Cap1.14
Enterprise Value/Revenue6.23
Enterprise Value/Gross Profit7.95
Enterprise Value/Ebitda-41.64
Forecast
1Y Price Target
$19.75Price Target Upside40.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.58
Revenue Forecast (FY)$99.95M
Bulls Say, Bears Say
Bulls Say
Published Long-term Clinical DurabilityProspective, FDA‑monitored 3‑year outcomes demonstrating an 82% median seizure reduction provide durable, peer‑reviewed evidence of efficacy. This strengthens clinician confidence, supports sustained procedure volumes, aids payer discussions, and differentiates the RNS System versus competitors over years.
High Gross Margins And Pricing StrengthConsistently very high gross margins (~80%+) imply strong unit economics and pricing power for the implanted system and services. Durable margins allow the company to fund R&D and commercial expansion while moving toward operating leverage, making the business more resilient to cost variability long term.
Commercial Momentum & Operating LeverageRising prescriber counts, account penetration and an expanding patient pipeline indicate scalable adoption. Combined with guided revenue growth and improving adjusted EBITDA, this suggests the sales model is converting into sustainable procedure growth and operating leverage over the next several quarters.
Bears Say
Elevated Leverage And Thin Equity CushionTotal debt near $70M versus a much smaller equity base raises refinancing and dilution risk. High leverage reduces financial flexibility for R&D and commercialization investments, increases sensitivity to cash flow swings, and could necessitate capital raises that dilute shareholders if cash burn persists.
Negative Cash Flow And Ongoing GAAP LossesTrailing‑12‑month negative operating and free cash flow indicate the business is still consuming cash despite margin strength. Losses translating into real cash outflows constrain runway, elevate financing needs, and can limit the company’s ability to sustain commercial expansion without further capital over the medium term.
Regulatory & Reimbursement UncertaintyA NUATILUS primary endpoint nuance and the exclusion of IGE from 2026 guidance create uncertain timing and scope for label expansion and payer coverage. Slow private payer adoption and the need for case‑by‑case advocacy can delay meaningful revenue contributions from new indications and constrain long‑term uptake.
NeuroPace News
NPCE FAQ
What was Neuropace, Inc.’s price range in the past 12 months?
Neuropace, Inc. lowest stock price was $7.56 and its highest was $19.60 in the past 12 months.
What is Neuropace, Inc.’s market cap?
Neuropace, Inc.’s market cap is $541.41M.
When is Neuropace, Inc.’s upcoming earnings report date?
Neuropace, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 61 days.
How were Neuropace, Inc.’s earnings last quarter?
Neuropace, Inc. released its earnings results on May 12, 2026. The company reported -$0.132 earnings per share for the quarter, beating the consensus estimate of -$0.23 by $0.098.
Is Neuropace, Inc. overvalued?
According to Wall Street analysts Neuropace, Inc.’s price is currently Undervalued.
Does Neuropace, Inc. pay dividends?
Neuropace, Inc. does not currently pay dividends.
What is Neuropace, Inc.’s EPS estimate?
Neuropace, Inc.’s EPS estimate is -0.21.
How many shares outstanding does Neuropace, Inc. have?
Neuropace, Inc. has 34,093,746 shares outstanding.
What happened to Neuropace, Inc.’s price movement after its last earnings report?
Neuropace, Inc. reported an EPS of -$0.132 in its last earnings report, beating expectations of -$0.23. Following the earnings report the stock price went up 0.063%.
Which hedge fund is a major shareholder of Neuropace, Inc.?
Currently, no hedge funds are holding shares in NPCE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NeuroPace Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.75 (40.17% Upside)
$19.75 (40.17% Upside)
Blogger Sentiment
Bullish
NPCE Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 59.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.4%
Last 30 Days ▲ 6.3%
Last 30 Days ▲ 6.3%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
23.91%
12-Months-Change
Fundamentals
Return on Equity
-120.74%
Trailing 12-Months
Asset Growth
-10.26%
Trailing 12-Months
Company Description
Neuropace, Inc.
NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.
NPCE Company Deck
NPCE Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial and clinical momentum: double-digit RNS revenue growth (CFO reported ~20% YoY excluding DIXI), raised full-year guidance, improved adjusted EBITDA outlook, robust clinical data (NAUTILUS 18-month and 3-year focal outcomes), and tangible AI/product roadmap progress. Offsetting risks include the NAUTILUS primary endpoint nuance, IGE revenue timing and payer coverage uncertainty, seasonally lower cash, and ongoing need for reimbursement work. Overall, management presented disciplined investment and operating leverage alongside meaningful opportunities that outweigh near-term risks.View all NPCE earnings summariesNPCE Stock 12 Month Forecast
Average Price Target
$19.75
▲(40.17% Upside)
Technical Analysis
Delcath Systems
―
Senseonics Holdings
―
Tactile Systems Technology
―
RxSight
―
Ceribell, Inc.
―
Ownership Overview
17.08% Insiders
9.77% Mutual Funds
42.19% Other Institutional Investors
15.78% Public Companies and
Individual Investors